Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 14.13%, which has investors questioning if this is right time ...

William Blair initiated coverage of Ocular Therapeutix (OCUL) with an Outperform rating and fair value of $18 per share. Ocular is a commercial ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

John Seymour, MBBS, FRACP, PhD, explains why BCL-2 was considered an undruggable target for so long and what led to the development of effective BCL-2 inhibitors.